FRS2

Across TCGA pan-cancer cohorts, FRS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FRS2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FRS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FRS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LSCC are the cancer types where FRS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.962	0.474	.007	17	view →
GBM	DFS	Median	All	0.812	0.694	.019	11	view →
LSCC	DFS	Tertile	III,IV	0.511	0.921	.047	2	view →
PDAC	DFS	Median	All	0.285	0.735	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FRS2–HNSC (DFS)

Open the HNSC breakdown →